Human Interleukin-6 (hIL-6)Product information
Product Pathways - Growth Factors/Cytokines
Human Interleukin-6 (hIL-6) #8904
|8904LC||50 µg (With Carrier)||---||In Stock||---|
|8904LF||50 µg (Carrier Free)||---||In Stock||---|
|8904SC||10 µg (With Carrier)||---||In Stock||---|
|8904SF||10 µg (Carrier Free)||---||In Stock||---|
Recombinant human IL-6 (hIL-6) Val30-Met212 (Accession #NM_000600) was produced in E. coli at Cell Signaling Technology.
Based on amino acid sequencing, greater than 60% of recombinant hIL-6 has a Met on the amino-terminal Val30 (sequence of MVPPG) and has a calculated MW of 20,943. The remainder starts at pro 32 (sequence of PPGED) or Pro33 (sequence of PGEDS). DTT-reduced protein migrates as a 23 kDa polypeptide and non-reduced protein migrates as a 22 kDa polypeptide due to intramolecular cystines.
>98% as determined by SDS-PAGE of 6 μg reduced (+) and non-reduced (-) recombinant hIL-6. All lots are greater than 98% pure.
The bioactivity of recombinant hIL-6 was determined in a TF-1 cell proliferation assay. The ED50 of each lot is between 0.2-0.7 ng/ml.
The purity of recombinant hIL-6 was determined by SDS-PAGE of 6 µg reduced (+) and non-reduced (-) recombinant hIL-6 and staining overnight with Coomassie Blue.
The proliferation of TF-1 cells treated with increasing concentrations of hIL-6 was assessed. After 48 hour treatment with hIL-6, cells were incubated with a tetrazolium salt and the OD450 - OD650 was determined.
Western blot analysis of extracts from TF-1 cells, untreated or treated with hIL-6 for 10 minutes, using Phospho-Stat1 (Tyr701) Antibody #9171 (upper) and Stat1 Antibody #9172 (lower).
Less than 0.01 ng endotoxin/1 μg hIL-6.
With carrier: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2 containing 20 μg BSA per 1 μg hIL-6. Carrier free: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2.
IL-6 is a potent inducer of the acute phase response and is produced by T cells, macrophages, fibroblasts, endothelial and other cells (1,2). IL-6 induces proliferation and differentiation and acts on B cells, T cells, thymocytes, and others. IL-6 in concert with TGFβ is important for developing Th17 responses. IL-6 binds to IL-6Rα and through this association induces gp130 homodimerization (1). gp130 homodimerization triggers the Jak/Stat cascade and the SHP2/Erk MAP kinase cascade (1,3,4). IL-6 also forms a complex with an IL-6Rα splice variant that is non-membrane associated (3).The IL-6/soluble IL-6Rα complex can then activate the gp130 signaling pathway on cells that express gp130 but not IL-6Rα (3). IL-6, through increasing expression of proangiogenic VEGF, may contribute to metastatic breast cancer (5).
- Kumar, J. et al. (2014) Br J Cancer 110, 133-45. Applications: Growth factors/cytokines.
- Kotobuki, Y. et al. (2012) Pigment Cell Melanoma Res 25, 219-30. Applications: Growth factors/cytokines.
Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!
- 3332 Jak1 Antibody
- 9872 Phosphate Buffered Saline (PBS-1X) pH7.2 (Sterile)
- 3331 Phospho-Jak1 (Tyr1022/1023) Antibody
- 9138 Phospho-Stat3 (Tyr705) (3E2) Mouse mAb
- 9131 Phospho-Stat3 (Tyr705) Antibody
- 9170 PhosphoPlus® Stat1 (Tyr701) Antibody Kit
- 9130 PhosphoPlus® Stat3 (Tyr705) Antibody Kit
- 9172 Stat1 Antibody
- 9139 Stat3 (124H6) Mouse mAb
This product is intended for research purposes only. The product is not intended to be used for therapeutic or diagnostic purposes in humans or animals.
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.